- Tevogen Bio begins pre-clinical effort for TVGN 920, signaling the start of its oncology treatment pipeline.
- Tevogen Bio created a data set containing known proteins in the HPV genome to identify targets, accelerating the pre-clinical process.
- 5.5 million women per year have HPV 16/18; of these 200,000 women per year are diagnosed with high grade dysplasia.
WARREN, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, recently announced its Artificial Intelligence effort, Tevogen.AI, had partnered with Microsoft (NASDAQ:MSFT), the world's leading AI company.
Using Microsoft's suite of advanced tools, Tevogen Bio is proactively investigating potential treatments for HPV to create a portfolio of oncology products. The company has developed a dataset of proteins from the HPV genome and is identifying cytotoxic T cell (CTL) targets to choose for a clinical trial for TVGN 920, its first oncology product. Through Tevogen's proprietary ExacTcell technology, where CTLs are trained to detect specific targets and then expanded, the company aims to be prepared to deliver an HPV-specific CTL treatment.